All In Biotech

Free tool

FAERS Monitor: Qulipta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215206 or its brand name (Qulipta, Atogepant). Reports on generic versions are filed under their own applications.

Reports

6,969

Serious

2,589

37% of reports

Hospitalization

663

Death reported

83

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • migraine1,224
  • drug ineffective829
  • headache672
  • nausea639
  • constipation474
  • fatigue446
  • dizziness276
  • therapy interrupted201
  • pain189
  • vomiting188
  • off label use184
  • decreased appetite182
  • weight decreased165
  • anxiety159
  • therapeutic product effect incomplete154

Reports by year received

View as table
YearReports
20161
20171
20193
20208
202128
20221,687
20231,716
2024999
20251,371
20261,155

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
migraineSignal1,22439.237.245,131
therapy interruptedSignal2018.57.41,325
constipationSignal4746.66.02,252
therapeutic product effect incompleteSignal1546.55.6719
headacheSignal6723.23.01,068
nauseaSignal6392.42.3561
decreased appetiteSignal1822.42.0144
drug ineffective8291.91.8375
weight decreased1651.81.557
fatigue4461.71.6142
anxiety1591.71.444
dizziness2761.71.575
vomiting1881.21.07
pain1890.90.81
off label use1840.60.540

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.